These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 37317996)
1. Faris A; Hadni H; Saleh BA; Khelfaoui H; Harkati D; Ait Ahsaine H; Elhallaoui M; El-Hiti GA J Biomol Struct Dyn; 2024 Jun; 42(9):4456-4474. PubMed ID: 37317996 [TBL] [Abstract][Full Text] [Related]
2. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives. Faris A; Hadni H; Ibrahim IM; Elhallaoui M J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041 [TBL] [Abstract][Full Text] [Related]
3. High-throughput virtual screening of phenylpyrimidine derivatives as selective JAK3 antagonists using computational methods. Faris A; Ibrahim IM; Hadni H; Elhallaoui M J Biomol Struct Dyn; 2024 Sep; 42(14):7574-7599. PubMed ID: 37539779 [TBL] [Abstract][Full Text] [Related]
4. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis. Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982 [TBL] [Abstract][Full Text] [Related]
5. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors. Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575 [TBL] [Abstract][Full Text] [Related]
6. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques. Wang JL; Cheng LP; Wang TC; Deng W; Wu FH J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751 [TBL] [Abstract][Full Text] [Related]
7. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold. Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405 [TBL] [Abstract][Full Text] [Related]
9. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3). Kaur M; Silakari O J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281 [TBL] [Abstract][Full Text] [Related]
10. Molecular Docking and Molecular Dynamics Simulation of New Potential JAK3 Inhibitors. Zhong Q; Qin J; Zhao K; Guo L; Li D Curr Comput Aided Drug Des; 2024; 20(6):764-772. PubMed ID: 37231719 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773 [TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors. Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331 [TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent, selective, covalent inhibitors of JAK3. Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786 [TBL] [Abstract][Full Text] [Related]
14. Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis. He L; Zhang J; Ling Z; Zeng X; Yao H; Tang M; Huang H; Xie X; Qin T; Feng X; Chen Z; Deng F; Yue X Bioorg Chem; 2024 Aug; 149():107499. PubMed ID: 38815476 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
16. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies. El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271 [TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis. He L; Pei H; Lan T; Tang M; Zhang C; Chen L Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. Zhu Y; Zheng X; Wang C; Sun X; Sun H; Ma T; Li Y; Liu K; Chen L; Ma X Bioorg Med Chem; 2020 Jan; 28(2):115254. PubMed ID: 31866272 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties. Somakala K; Tariq S; Amir M Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]